Premium
Going back to class I: MHC and immunotherapies for childhood cancer
Author(s) -
Haworth Kellie B.,
Leddon Jennifer L.,
Chen ChunYu,
Horwitz Edwin M.,
Mackall Crystal L.,
Cripe Timothy P.
Publication year - 2015
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.25359
Subject(s) - medicine , mhc class i , immunotherapy , blood cancer , cancer immunotherapy , cancer , clinical trial , pediatric cancer , major histocompatibility complex , childhood cancer , immunology , oncology , antigen
After decades of unfulfilled promise, immunotherapies for cancer have reached a tipping point, with several FDA approved products now on the market and many more showing promise in both adult and pediatric clinical trials. Tumor cell expression of MHC class I has emerged as a potential determinant of the therapeutic success of many immunotherapy approaches. Here we review current knowledge regarding MHC class I expression in pediatric cancers including a discussion of prognostic significance, the opposing influence of MHC on T‐cell versus NK‐mediated therapies, and strategies to reverse or circumvent MHC down‐regulation.Pediatr Blood Cancer 2015;62:571–576. © 2014 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals, Inc.